Dose Escalation in Prostate Cancer Treatment
Author Information
Author(s): Dearnaley D P, Hall E, Lawrence D, Huddart R A, Eeles R, Nutting C M, Gadd J, Warrington A, Bidmead M, Horwich A
Primary Institution: Institute of Cancer Research
Hypothesis
Does escalating the dose of conformal radiotherapy improve PSA control in prostate cancer patients?
Conclusion
Increasing the radiotherapy dose from 64 to 74 Gy may improve long-term PSA control, but a larger treatment margin of 1.5 cm is unnecessary and leads to more side effects.
Supporting Evidence
- Freedom from PSA failure was higher in the 74 Gy group compared to the 64 Gy group.
- Statistically significant increases in acute bladder side effects were seen after treatment in the men receiving 74 Gy.
- Late bowel side effects were more common in the 74 Gy and 1.5 cm margin groups.
Takeaway
This study looked at whether giving a higher dose of radiation helps men with prostate cancer live longer without their cancer coming back. It found that a higher dose might help, but using a bigger safety margin isn't needed and can cause more side effects.
Methodology
A phase III pilot study with a 2 by 2 factorial design comparing 64 Gy and 74 Gy doses with different treatment margins.
Potential Biases
Potential bias due to the early termination of the study and the lack of blinding.
Limitations
The study was stopped early with only 126 men randomized instead of the planned 350, limiting the power of the results.
Participant Demographics
Median age of participants was 67 years, with a mix of T1b-T3b N0 M0 adenocarcinoma cases.
Statistical Information
P-Value
0.10
Confidence Interval
95% CI 58–81% for 74 Gy group
Statistical Significance
p=0.10
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website